ZYME
Zymeworks Inc.
Zymeworks Inc. (ZYME) has 8 SEC Form 4 filings (19 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Jul 6, 2026.
Insiders have net sold $1.3M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Kenneth H. Galbraith
- Employees:264
- HQ:Middletown, DE, US
- IPO:2017-04-28
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3.4M
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Market Cap
$1.8B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Hollywood MarkFirst filing | EVP & Chief Operating Officer | Sale | 6,120 | $139K | Jan 13 | SEC ↗ |
| Chief Scientific Officer | Sale | 9,560 | $217K | Jan 12 | SEC ↗ | |
| Chair & CEO | Sale | 30,424 | $690K | Jan 12 | SEC ↗ | |
| EVP & Chief Medical Officer | Sale | 9,310 | $211K | Jan 12 | SEC ↗ | |
Galbraith KennethFirst filing | Chair & CEO | Sale | 54,343 | $1.4M | Jan 5 | SEC ↗ |
Moore Paul AndrewFirst filing | Chief Scientific Officer | Sale | 20,110 | $505K | Jan 5 | SEC ↗ |
Smith Jeffrey T LFirst filing | EVP & Chief Medical Officer | Sale | 10,538 | $264K | Jan 5 | SEC ↗ |
Related companies
Zymeworks Inc. is in the Healthcare sector.